Cell populations which co-express CD49c and CD90

• US 20070224177A1
• Filed: 02/07/2007
• Published: 09/27/2007
• Est. Priority Date: 09/20/2002
• Status: Abandoned Application

• Current Assignee: Garnet Biotherapeutics Incorporated
• Original Assignee: Garnet Biotherapeutics Incorporated
• Inventors: Ragaglia, Vanessa, Kopen, Gene, Wagner, Joseph, Ho, Tony, Rutkowski, J., Herring, W., Righter, William
• Application Number:
  US11/703,479
• Publication Number:
  US 20070224177A1
• Time in Patent Office: Days
• US Class Current: 424/93.210
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: C12N 2501/06 Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
• CPC Class Codes: C12N 2501/405 Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
• CPC Class Codes: C12N 2506/11 from blood or immune system cells
• CPC Class Codes: C12N 5/0634 Cells from the blood or the immune system
• CPC Class Codes: C12N 5/0657 Cardiomyocytes; Heart cells

Abstract

Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are made by selecting from a cultured source of a cell population which co-express CD49c and CD90 and modifying the cell population. The committed progenitor cells can be employed to treat a human suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition and to formulate pharmaceutical compositions. In a further embodiment, a substantially homogenous population of cells which co-express CD49c, CD90 and at least one cardiac-related transcription factor is made and can be used to treat a human suffering from a cardiac condition.

Claims

1. (canceled)

2. A method of treating a myocardial infarction in a human, comprising the step of administering a substantially homogenous cell population which co-expresses CD49c, CD90 and at least one cardiac-related transcription factor to the human.

3. The method of claim 2, wherein the cardiac-related transcription factor is selected from the group consisting of GATA4, Irx4 and Nkx2.5.

4. The method of claim 2, wherein the substantially homogenous cell population co-expresses CD49c, CD90, GATA4, Irx4 and Nkx2.5.

5. The method of claim 2, wherein the substantially homogenous cell population co-expresses CD49c, CD90, telomerase, GATA4, Irx4 and Nkx2.5.

6. A method of treating a myocardial infarction in a human, comprising the steps of:

a) culturing a source of a cell population under a low oxygen condition;

b) treating the cultured source of the cell population with a protein kinase C inhibitor and a DNA methylation inhibitor; and

c) administering the treated cell population to the human.

7. The method of claim 6, wherein the treated cell population is administered proximate to the myocardial infarction.

8. The method of claim 7, wherein the treated cell population is administered into a cardiac muscle.

9. The method of claim 6, further including selecting from the treated cell population, a population of cells which co-expresses CD49c, CD90, and at least one cardiac-specific marker.

10. The method of claim 9, wherein the selected cell population further includes cells which express telomerase.

11. The method of claim 9, wherein the cardiac-specific marker is selected from the group consisting of GATA4, Irx4 and Nkx2.5.

12. The method of claim 6, wherein the source of cell population includes a bone marrow source.

13. A method of treating a myocardial infarction in a human, comprising the steps of:

a) treating a cell population which co-expresses CD49c and CD90 with a protein kinase C inhibitor and a DNA methylation inhibitor; and

b) administering the treated cells to the human.

14. The method of claim 13, wherein the cell population is derived from bone marrow.

15. The method of claim 13, wherein the cell population further includes cells which co-express telomerase.

16. The method of claim 13, wherein the cell population expresses at least one cardiac-related transcription factor selected from the group consisting of GATA4, Irx4 and Nkx2.5.

17. A method of treating a congestive heart failure in a human, comprising the step of administering a substantially homogenous cell population which co-expresses CD49c, CD90 and at least one cardiac-related transcription factor to the human.

18. The method of claim 17, wherein the substantially homogenous cell population co-expresses CD49c, CD90, GATA4, Irx4 and Nkx2.5.

19. The method of claim 17, wherein the substantially homogenous cell population co-expresses CD49c, CD90, telomerase, GATA4, Irx4 and Nkx2.5.

20. A method of treating a congestive heart failure in a human, comprising the steps of:

a) culturing a source of a cell population under a low oxygen condition;

b) treating the cultured source of the cell population with a protein kinase C inhibitor and a DNA methylation inhibitor; and

c) administering the treated cell population to the human.